logo

AIM

AIM ImmunoTech·AMEX
--
--(--)
--
--(--)
3.67 / 10
Netural

Fund-flow data show a split pattern—small, medium, and large orders lean positive, but block and extra-large flows are negative—yielding a 7.35/10 score and a 'good' label. Meanwhile, analyst coverage is unanimous at 'Strong Buy' from Ascendiant Capital, yet historical prediction accuracy is poor (0% win rate). This divergence between positive capital momentum and unreliable analyst calls adds complexity to the investment narrative.

FundamentalSentiment(3.67)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-12-08
InstitutionAscendiant Capital
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for AIM?
  • AIM holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.67/10 (Netural).